|Recombinant Human OSTM1 protein (Catalog#10913-H08H)|
|0.2 μm filtered solution in PBS with 5% trehalose|
|Produced in rabbits immunized with purified, recombinant Human OSTM1 extracellular domain (rh OSTM1; Catalog#10913-H08H; NP_054747.2; Met 1-Pro 284). OSTM1 specific IgG was purified by human OSTM1 affinity chromatography.|
ELISA: 0.5-1.0 μg/mL
This antibody can be used at 0.5-1.0 μg/mL with the appropriate secondary reagents to detect Human OSTM1. The detection limit for Human OSTM1 is 0.00245 ng/well .
|This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.|
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Osteopetrosis-associated transmembrane protein 1 (OSTM1) is a Single-pass type I membrane protein. It is expressed in many hematopoietic cells of the myeloid and lymphoid B- and T-lineages. The analysis of OSTM1 association with CLCN7 demonstrated that OSTM1 requires CLCN7 to localize to lysosomes, whereas the formation of a CLCN7-OSTM1 complex is required to stabilize CLCN7. The researches found that OSTM1 plays a major role in myelopoiesis and lymphopoiesis and provided evidence of a crosstalk mechanism between hematopoietic cells for osteoclast activation. Thus, OSTM1 has a important role in osteoclast function and activation. The loss of function of OSTM1 results in deregulation of multiple hematopoietic lineages in addition to osteoclast lineage, OSTM1-defect patients display the most severe recessive osteopetrotic phenotype and die at early ages. Furthermore, it is suggested that OSTM1 has a primary role in neural development not related to lysosomal dysfunction. The canonical Wnt/beta-catenin signaling pathway may be a molecular basis for OSTM1 mutations and severe autosomal recessive osteopetrosis (ARO).
1. Chalhoub, N. et al., 2003, Nat Med. 9 (4): 399-406.
2. Quarello, P. et al., 2004, J Bone Miner Res. 19 (7): 1194-1199.
3. Lange, PF. et al., 2006, Nature. 440 (7081): 220-223
4. Maranda, B. et al., 2008, J Bone Miner Res. 23 (2): 296-300.
5. Feigin, ME.et al., 2008, Cell Signal. 20 (5): 949-957.
6. Pata, M.et al., 2008, J Biol Chem. 283 (45): 30522-30530.